Vertex Pharmaceuticals Inc.

NMS : VRTX
Pharmaceuticals
Cambridge MA
IW Best50N/A
2012 Revenue (US$ Millions)$1,527
2011 Revenue (US$ Millions)$1,411
Revenue Growth (%)8.25%
Net Income (US$ Millions)($107)
Common Shares Outstanding (Millions)$217
Earnings Per Share (US$)($0.50)
Total Equity (US$ Millions)$999
Profit Growth (%)-461.91
Profit Margin (%)-7.01%
Return On Equity (%)-13.60%
Long Term Debt (US$ Millions)$415
Debt To Equity Ratio (%)0.42%
Market Capitalization (US$ Millions)$9,104
Total Assets (US$ Millions)$2,759
Return on Assets (%)-4.86
Current Assets (US$ Millions)$1,590
Inventories (US$ Millions)$30
Current Liabilities (US$ Millions)$433
Cost of Goods Sold (US$ Millions)$237
Asset Turnover0.55
Inventory Turnover3.31